Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background and objectives There is concern about potential deleterious effects of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs) in patients with coronavirus disease 2019 (COVID-19). Patients with kidney failure, who often use ACEis/ARBs, are at higher risk of more severe COVID-19. However, there are no data available on the association of ACEi/ARB use with COVID-19 severity in this population.
Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure Maria Jose Soler, Marlies Noordzij, Daniel Abramowicz, Gabriel de Arriba, Carlo Basile, Marjolijn van Buren, Adrian Covic, Marta Crespo, Raphael Duivenvoorden, Ziad Massy, Alberto Ortiz, Emilio Sanchez, Emily Petridou, Kathryn Stevens, Colin White, Priya Vart, Ronald Gansevoort CJASN Jun 2021, CJN.18961220; DOI: 10.2215/CJN.18961220
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
